Rapid Therapeutic Science Laboratories Inc logo

RTSL - Rapid Therapeutic Science Laboratories Inc News Story

$0.71 -0.0  -2.5%

Last Trade - 27/11/20

Small Cap
Market Cap £97.6m
Enterprise Value £97.9m
Revenue £105k
Position in Universe 4224th / 6429

Rapid Therapeutic Enters Letter of Intent to Expand Production Capability to 3,000,000 MDI and $100,000,000 in Revenue Annually

Wed 30th September, 2020 11:00am
For best results when printing this announcement, please click on link below:

DALLAS, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science
Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol
manufacturing and marketing company focused on employing FDA-approved Metered
Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD,
CBG, and CBN, announces it has signed a letter of intent (LOI) to acquire all
of the assets of Razor Jacket, LLC based in Hillsboro, Oregon in a cash and
stock transaction.

Razor Jacket currently supplies medical grade CBD and CBG Isolate to RTSL.
These isolates are the active ingredient in RTSL’s base formulas. An
“isolate” is the ultra-pure form of any single cannabinoid, having no
other chemical ingredients. This vertical acquisition assures RTSL of access
to up to 150 kilograms a month of 99.9% pure isolate. Any isolate not consumed
in RTSL’ primary products will be marketed as medical or pharmaceutical
grade isolate directly to the health and wellness space. Without adding any
additional capital, the lab can make sufficient production to assure RTSL can
make in excess of 3,000,000 MDI units annually. Further, the acquisition will
reduce RTSL’s cost of goods sold by approximately 50% per MDI unit.

RTSL’s CEO, Donal R. Schmidt, Jr. states, “There are a lot of
manufacturers in the market who make fairly good isolate, but not good enough
to use in the pulmonary route of administration. Razor Jacket’s highly
customized state-of-the-art lab, which we are relocating to north Texas, is
unrivaled and parts of its GMP which are unique in the isolate arena are going
to be patented by RTSL as part of the trade. We also inherit a formidable
marketing and scientific team with deep and important ties to the
pharmaceutical space who are also relocating fulltime to Dallas. This broadens
our footprint and moves us closer to our ultimate goal of having a full cGMP
facility and ultimately FDA approved products. Plus by controlling our own
isolate manufacturing we significantly improve the time previously spent on
quality control related to sourcing of finished product. It is a real cost
saver to us.”

RTSL’s Sr. VP, Sean Berrier, states, “We formally tested over 70 other
isolate manufacturers’ CBD the last two (2) years. No one else’s product
was even close in quality. We essentially vetted everyone in the market. Razor
Jacket’s product is far superior to everyone else’s in my opinion.
Bringing them on board is a real advantage in this space.”

Razor Jacket’s CEO, Ryan Johnson states, “We look forward to relocating to
Dallas. The aerosol space is a perfect fit for the medical grade isolate we
have been producing. Our unique relationship with major pharmaceutical players
gives us a strategic advantage in how to make medical grade products as well
as position the company for a potential buyout from big pharma.”

Schmidt also states, “Ryan Johnson will head up Marketing for RTSL and sit
on the board of RTSL under a designation of board rights. I am looking forward
to working with someone of his caliber in sales and marketing.”  

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulating and manufacturing
pressurized metered dose inhalers (pMDI) that contain and properly aerosolize
proprietary formulae consisting of one or more cannabinoid compounds, such as
CBD, CBG, and/or CBN. The Company’s Rxoid™ and nhāler product lines are
manufactured in compliance with Good Manufacturing Practices (GMP), on
FDA-listed equipment. Note that while cannabinoids such as CBD, CBG and CBN
are not yet approved by the FDA, under the laws of Texas and of many other
states, it is legal to consume, sell and export them to legal jurisdictions.

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API)
(drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is
generally the most efficient delivery method for an API other than an IV. In
addition, MDIs are less expensive than any other route of delivery, based on
the net cost per bioactive mg as tested in blood serum levels. However, MDIs
are expensive to formulate and difficult to manufacture in order to deliver
cannabinoid compounds to the level required by the FDA and FTC truth in
labelling laws. Ideally, a properly formulated, properly manufactured MDI
containing cannabinoids will deliver exactly the same dose on its first use as
well as its 100th use.

RTSL’s MDIs are a safe and technically superior replacement for vape pens,
mods and all-in-one products because they use no heat, function perfectly
without using dangerous ingredients, and deliver a 98% bioavailable dose of
CBD and/or cannabinoids directly to the systemic blood stream. This allows
RTSL to manufacture a scientifically sound and superior alternative to all
other cannabinoid vaping systems in a market estimated to be $5 billion in
annual sales.

RTSL products will continue to be sold directly to pharmacies, physicians and
other healthcare providers who treat GAD, PTSD and other stress and anxiety
disorders. nhāler can be purchased online at www.nhaler.com. Rxoid™
currently is unavailable to purchase as its website is being updated. RTSL
also produces white label products for select commercial clients.

We encourage all individuals to do their own research regarding cannabinoids,
the use of MDI and our products. RTSL makes no claims about therapeutic
benefits of its products. None of our products are intended to diagnose,
treat, cure, or prevent any disease. Always consult a physician prior to using
any cannabinoid product. If you experience any adverse reaction stop use
immediately and seek appropriate medical attention. RTSL’s products are not
approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

Visit our corporate website at www.rtslco.com.

Forward-Looking Statements 

This press release may contain forward-looking statements. In particular, when
used in the preceding discussion, the words “may,” “could,”
“expect,” “intend,” “plan,” “seek,” “anticipate,”
“believe,” “estimate,” “predict,” “potential,” “continue,”
“likely,” “will,” “would” and variations of these terms and
similar expressions, or the negative of these terms or similar expressions are
intended to identify forward-looking statements. Any statements made in this
news release other than those of historical fact, about an action, event or
development, are forward-looking statements. These statements involve known
and unknown risks, uncertainties and other factors, which may cause the
results of RTSL, its divisions and concepts to be materially different than
those expressed or implied in such statements. These risk factors and others
are included from time to time in filings made by RTSL with the Securities and
Exchange Commission, including, but not limited to, in the “Risk Factors”
sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have
filed, and file from time to time, with the U.S. Securities and Exchange
Commission. These reports are available at www.sec.gov. Other unknown or
unpredictable factors also could have material adverse effects on RTSL’s
future results and/or could cause our actual results and financial condition
to differ materially from those indicated in the forward-looking statements.
The forward-looking statements included in this press release are made only as
of the date hereof. RTSL cannot guarantee future results, levels of activity,
performance or achievements. Accordingly, you should not place undue reliance
on these forward-looking statements. We undertake no obligation to update
publicly any of these forward-looking statements to reflect actual results,
new information or future events, changes in assumptions or changes in other
factors affecting forward-looking statements, except to the extent required by
applicable laws. If we update one or more forward-looking statements, no
inference should be drawn that we will make additional updates with respect to
those or other forward-looking statements.

Donal (Don) R. Schmidt, Jr.
Chairman and CEO

Phone: 800-497-6059
Fax: 877-676-8527


GlobeNewswire, Inc. 2020
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.